Ahmed I. El-Tantawy

Mr. Ahmed I. El-Tantawy

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2023 in Surfaces and Interfaces
Verified
Journal Article
Closed access
AEAhmed I. El-Tantawy
Ahmed I. El-Tantawy
SSShimaa Saeed
Shimaa Saeed
RNRana R. Neiber
Rana R. Neiber
WEWael H. Eisa
Wael H. Eisa
AAAbdel Aleem H. Abdel Aleem
Abdel Aleem H. Abdel Aleem
MMMai S. Maize
Mai S. Maize

6 June 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AEAhmed I. El-Tantawy
Ahmed I. El-Tantawy
EEElshaymaa I. Elmongy
Elshaymaa I. Elmongy
SSShimaa Saeed
Shimaa Saeed
AAAbdel Aleem H. Abdel Aleem
Abdel Aleem H. Abdel Aleem
RBReem Binsuwaidan
Reem Binsuwaidan
NANour Attia
Nour Attia
Newly synthesized mono- and bis-thioureidophosphonate (MTP and BTP) analogues in eco-friendly conditions were employed as reducing/capping cores for 100, 500, and 1000 mg L−1 of silver nitrate. The physicochemical properties of silver nanocomposites (MTP(BTP)/Ag NCs) were fully elucidated using spectroscopic and microscopic tools. The antibacterial activity of the nanocomposites was screened against six multidrug-resistant pathogenic strains, comparable to ampicillin and ciprofloxacin commercial drugs. The antibacterial performance of BTP was more substantial than MTP, notably with the best minimum inhibitory concentration (MIC) of 0.0781 mg/mL towards Bacillus subtilis, Salmonella typhi, and Pseudomonas aeruginosa. Among all, BTP provided the clearest zone of inhibition (ZOI) of 35 ± 1.00 mm against Salmonella typhi. After the dispersion of silver nanoparticles (AgNPs), MTP/Ag NCs offered dose-dependently distinct advantages over the same nanoparticle with BTP; a more noteworthy decline by 4098 × MIC to 0.1525 × 10−3 mg/mL was recorded for MTP/Ag-1000 against Pseudomonas aeruginosa over BTP/Ag-1000. Towards methicillin-resistant Staphylococcus aureus (MRSA), the as-prepared MTP(BTP)/Ag-1000 displayed superior bactericidal ability in 8 h. Because of the anionic surface of MTP(BTP)/Ag-1000, they could effectively resist MRSA (ATCC-43300) attachment, achieving higher antifouling rates of 42.2 and 34.4% at most optimum dose (5 mg/mL), respectively. The tunable surface work function between MTP and AgNPs promoted the antibiofilm activity of MTP/Ag-1000 by 1.7 fold over BTP/Ag-1000. Lastly, the molecular docking studies affirmed the eminent binding affinity of BTP over MTP—besides the improved binding energy of MTP/Ag NC by 37.8%—towards B. subtilis-2FQT protein. Overall, this study indicates the immense potential of TP/Ag NCs as promising nanoscale antibacterial candidates.

19 September 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
EAElShimaa Ahmed Mohamed Abousaada
ElShimaa Ahmed Mohamed Abousaada
AGAsmaa Galal-Khallaf
Asmaa Galal-Khallaf
KGKhaled Mohammed Geba
Khaled Mohammed Geba
MEMohammed Amin El-Bahnasawye
Mohammed Amin El-Bahnasawye
MHMona Kotp Hussein
Mona Kotp Hussein
ITIbrahim Tantawy
Ibrahim Tantawy
Background: Type 2 diabetes mellitus (T2DM) and hyperlipidemia are interrelated metabolic disorders that significantly increase cardiovascular risk. Thiazolidinediones are known insulin sensitizers, whereas quinoline derivatives possess diverse pharmacological activities. To explore their complementary activity, we designed a novel hybrid compound integrating a thiazolidinedione core with a quinoline moiety via a carbon spacer. Materials and Methods: The hybrid molecule was synthesized through a straightforward route and structurally confirmed by spectroscopic analyses. Zebrafish (Danio rerio) were employed as an in vivo model, with hyperglycemia induced by immersion in 100 mM glucose monohydrate for 12 days. Fish were divided into treatment groups receiving 20 or 80 mg/kg of the compound, alongside the controls. Biochemical parameters (glucose, triglycerides, insulin) and gene expression levels (NF-κB, ACOX1, ACCα) were assessed. In silico docking was conducted to predict molecular interactions. Results: Treatment with the hybrid compound significantly restored glucose, triglyceride, and insulin levels. High-dose administration suppressed NF-κB expression and normalized ACOX1 levels, while both low- and high-dose treatments downregulated ACCα compared with untreated hyperglycemic controls. Computational studies supported multitarget activity through predicted binding to PPAR-α and ACOX1. Conclusions: Quinoline-Thiazolidine-2,4-Dione demonstrated strong antihyperglycemic and antihypertriglyceridemic activities in zebrafish models, supported by in silico validation.